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Abstract
Background: Chronic injury deregulates cellular homeostasis and induces a number of alterations leading
to disruption of cellular processes such as cell cycle checkpoints and apoptosis, driving to carcinogenesis.
The stress protein heme oxygenase-1 (HO-1) catalyzes heme degradation producing biliverdin, iron and
CO. Induction of HO-1 has been suggested to be essential for a controlled cell growth. The aim of this
work was to analyze the in vivo homeostatic response (HR) triggered by the withdrawal of a potent
carcinogen, p-dimethylaminoazobenzene (DAB), after preneoplastic lesions were observed. We analyzed
HO-1 cellular localization and the expression of HO-1, Bcl-2 and cell cycle related proteins under these
conditions comparing them to hepatocellular carcinoma (HC).
Methods:  The intoxication protocol was designed based on previous studies demonstrating that
preneoplastic lesions were evident after 89 days of chemical carcinogen administration. Male CF1 mice (n
= 18) were used. HR group received DAB (0.5 % w/w) in the diet for 78 days followed by 11 days of
carcinogen deprivation. The HC group received the carcinogen and control animals the standard diet
during 89 days. The expression of cell cycle related proteins, of Bcl-2 and of HO-1 were analyzed by
western blot. The cellular localization and expression of HO-1 were detected by immnunohistochemistry.
Results: Increased expression of cyclin E/CDK2 was observed in HR, thus implicating cyclin E/CDK2 in
the liver regenerative process. p21cip1/waf1 and Bcl-2 induction in HC was restituted to basal levels in HR.
A similar response profile was found for HO-1 expression levels, showing a lower oxidative status in the
carcinogen-deprived liver. The immunohistochemical studies revealed the presence of macrophages
surrounding foci of necrosis and nodular lesions in HR indicative of an inflammatory response.
Furthermore, regenerative cells displayed changes in type, size and intensity of HO-1 immunostaining.
Conclusion: These results demonstrate that the regenerative capacity of the liver is still observed in the
pre-neoplastic tissue after carcinogen withdrawal suggesting that reversible mechanism/s to compensate
necrosis and to restitute homeostasis are involved.
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Background
Primary liver carcinoma or hepatocellular carcinoma
(HC) constitutes the most common visceral malignant
tumor and in some populations is the most common
overall [1]. It arises, mainly, from hepatocytes, the major
cell type of liver and it can be also derived from character-
istic morphological cells named "oval cells" after the
exposure to hepatocarcinogens, by an irreversible block-
age in the process of normal differentiation and by gener-
ation of immortal transformed cells with proliferative
potential. Dedifferentiation of normal mature hepato-
cytes is also accepted as a theory to postulate that a ran-
dom clonal, near 20%, origin of HC is seen in
experimental rat chemical hepatocarcinogenesis [2].
There are several models available to study the mecha-
nisms of development of liver cancer in vivo. Cancer devel-
opment involves both genotoxic and cell proliferative
stages. Cell proliferation is essential for the carcinogenic
process, not only to induce heritable damage to the DNA
sequence during the initiation of cancer, but also to clonal
expand these initiated cells during promotion [3]. There
are several different methods to induce hepatic cell prolif-
eration, among them partial hepatectomy, the use of a
necrogenic dose of an initiator and fasting/refeeding with
a subnecrogenic dose of initiator [3].
The liver has two main capacities, one is to regenerate after
injury or resection [4] and the other is to self-regulate its
growth and final mass development [5]. However, a
reduction in liver cell mass, due to cell loss and/or cell
atrophy, triggers a rapid regenerative response tailored to
replace the lost tissue, resulting in an almost complete res-
titution of hepatic mass and function [6]. Partial hepatec-
tomy triggers hepatocyte proliferation whereas excessive
liver mass is regulated by apoptosis [7]. In addition to
hepatocytes and non-parenchymal cells, the liver contains
"stem" cells which can generate a transitory compartment
of precursor hepatocytes, named oval cells [5,8].
Cell cycle regulators controlling G1 phase progression are
frequently involved in the carcinogenesis of many human
cancer types [9]; even of HC [10]. There are at least 9 cdks.
These kinases are activated by D-type cyclins (D1, D2, D3)
and cyclin E, and inhibited by two families of cdk inhibi-
tors, the INK and Cip/Kip families [11].
Aberrant cell proliferation and abnormal expression of
cell cycle related proteins are observed in inflammatory
disorders. Cellular over expression of heme oxygenase-1
(HO-1), the anti-inflammatory and anti-oxidative stress
protein that catalyzes heme degradation producing
biliverdin, iron and CO, up-regulates p21cip1/waf1, dimin-
ishes cell growth proliferation and confers marked resist-
ance to apoptosis. Consequently up-regulation of p21cip1/
waf1 contributes to the altered pattern of cell growth and
resistance to apoptosis [12].
The multistep process of liver regeneration comprises at
least two critical phases: the transition of the quiescent
hepatocyte into the cell cycle (priming) and the progres-
sion beyond the restriction point in the G1 phase. The
priming phase is characterized by the expression of imme-
diate early genes which causes secondary activation of
multiple genes and plays an important role in the initia-
tion of hepatic regeneration. Activation of proto-onco-
genes in the immediate early gene response involves both
transcriptional and post-transcriptional mechanisms [7].
We have established an experimental mouse model of HC
by the administration of DAB [13,14]. In this model, DAB
metabolization generates an oxidative process, leading to
inflammation and consequent liver injury reflected by
foci of necrosis with decreased HO-1 immunohistochem-
ical expression [14]. Under this experimental protocol, it
was possible to identify early preneoplastic lesions which
were characterized by proliferation of phenotipically
altered hepatic foci (AHF) and oval cells after chronic
exposure to DAB and to develop adenomas and hepato-
carcinomas with an efficiency of 100% [14].
The aim of this work was to explore the liver capacity to
restore homeostasis under carcinogen withdrawal analyz-
ing the expression and cellular localization patterns of the
cellular key adaptive protein HO-1 and to compare it with
the continuous carcinogen administration. We have also
investigated the expression of cell cycle related proteins
and Bcl-2 during chemical induced hepatocarcinogenesis
to evaluate whether the expression of these proteins was
affected in different ways by deprivation of the carcinogen
in this in vivo model.
Methods
Chemicals
Chemicals were reagent grade and purchased from Sigma
Chemical Co. (St. Louis, MO, USA).
Animals and treatment
Male CF1 mice (30 g) (n = 18) received a standard labora-
tory diet (SLD) (Purina 3, Asociación de Cooperativas
Argentinas, San Nicolás, Buenos Aires, Argentina) supple-
mented or not with p-dimethylaminoazobenzene (DAB,
0.5 % w/w) under the intoxication protocol shown in Fig.
1. Animals with chemical induced hepatocellular carci-
noma (HC group, n = 6) received the carcinogen during
89 days, when preneoplastic lesions were evident as previ-
ously reported [14]. The group of homeostatic response
(HR, n = 6) received SLD since day 78; this time point was
selected according to preliminary results demonstrating
that optical proliferative morphological features were evi-BMC Cancer 2006, 6:286 http://www.biomedcentral.com/1471-2407/6/286
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dent, indicative of a liver adaptive response by histologi-
cal confirmation. Control animals (n = 6) received SLD
for the whole period studied. All animals received food
and water ad libitum.
Throughout the study, all animals were inspected at least
twice daily. Body weight and food consumption were
measured at intervals throughout the study. Food was
removed from animals 16 hours before they were sacri-
ficed under ether anesthesia at the indicated times.
All animals received human care and were treated in
accordance with guidelines by the Animal Care and Use
Committee of the Argentine Association of Specialists in
Laboratory Animals (AADEALC) and in accordance with
the UK Guidelines for the Welfare of Animals in Experi-
mental Neoplasm (UK Coordinating Committee on Can-
cer Research, London, 1998).
Protein extraction and western blotting
The protein extraction from liver tissue and western blot
were performed as previously described in [10]. The fol-
lowing polyclonal antibodies were used: goat CDK2
(1:300), goat CDK4 (1:300), rabbit cyclin E (1:100), goat
p21cip1/waf1 (1:400), goat Bcl-2 (1:300) (Santa Cruz Bio-
tech, Santa Cruz, CA, USA) and rabbit HO-1 (1:300)
(Stressgen, Victoria, Canada). Goat actin (1:400) was used
as a loading control. For quantification of immunoblots,
relative intensity of bands was quantified by densitometry
using Image Master Image Analysis software (Amersham-
Pharmacia Biotech). Control for loading and transfer was
obtained by probing with anti-β actin. The values of the
different protein bands were normalized to the intensity
of the loading control.
Immunohistochemistry study
Complete necropsy of all animals was performed and
liver samples were immediately processed. A random sec-
tion, about 4 mm thick, was removed from the median,
left lateral and right lateral lobes of the liver. This opera-
tion was repeated to examine samples from each liver.
Additional sections were taken of grossly visible lesions
not included within the above sections.
All sections were cut 3–5 µm thick from buffered forma-
lin-fixed, paraffin-embedded tissue. After deparaffiniza-
tion, sections were stained with haematoxylin-eosin
(H&E), periodic acid-Schiff (PAS) reagent, Gomori's silver
impregnation for reticulin and Prussian blue iron meth-
ods.
Liver foci as well as tumor histology were identified
according to optical morphological published criteria
[15].
Immunohistochemisty studies were performed in serial
sections obtained from the paraffin blocks used for the
histological diagnosis. They were deparaffinized with
three 10 min. changes of xylene and then were hydrated
in decreasing concentrations of ethanol and rinsed with
Experimental protocol Figure 1
Experimental protocol.BMC Cancer 2006, 6:286 http://www.biomedcentral.com/1471-2407/6/286
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water. Prior to staining, the slides were placed in 10 mM
sodium citrate buffer pH 6 in a microwave oven (5 × 2
min at 750 W, with a cooling period of 6 min after each
treatment).
Sections were pretreated with horse normal serum,
diluted at 1:20, for 20 min. and then were incubated with:
1) a rabbit polyclonal antibody against HO-1, diluted at
1:500, overnight; 2) biotinylated anti-rabbit immu-
noglobulins serum diluted at 1:15 for 30 min and 3) alka-
line phosphatase labeled streptavidin diluted at 1:15 for
30 min. Alkaline phosphatase activity was developed with
the Fast-Red system (DAKO). Slides were lightly counter-
stained with H&E. All incubations were done at room
temperature, and all washings were performed with phos-
phate-buffered saline buffer (pH 7.5)
Control sections used for determination of antibody reac-
tion specificity: (a) tissue positive control (sections of
mouse spleen) and (b) negative technique control (serial
sections of each sample omitting the primary antibody).
The HO-1 immunostaining was qualitatively evaluated by
the presence of positive or negative staining, in addition
to the type of cells staining positive.
Statistics
Statistical analysis was performed by Student's t-test.
Results are presented as means ± SD and significance was
defined as P < 0.05.
Results
Cyclin E and CDK2 protein levels are increased after 
carcinogen withdrawal
Cell cycle progression is driven by activation of several
CDKs that are regulated by CDK inhibitors. Hence, we
analyzed the hepatic expression of cyclin E, CDK2, CDK4
and the cell cycle inhibitor p21cip1/waf1 in animals receiv-
ing continuous dietary DAB (HC) and in the HR animals.
HR was produced by carcinogen deprivation as described
in Experimental Procedures. CDK2 expression increased
in HR (49%, P < 0.05) respect to control and HC groups,
while no variation was detected in CDK4 in any of the
tested groups (Fig. 2). A prominent enhancement in cyclin
E expression was observed in both HC (53%, P < 0.05)
and HR (51%, P < 0.05), indicating that the induction of
cyclin E expression provoked by the carcinogen could not
be repressed by the carcinogen deprivation, at least during
the assayed period. All together these results implicated
cyclin E and its associated CDK (CDK2) in the regenera-
tive process.
p21cip1/waf1, initially identified as a CDK inhibitor, plays
an important role in the DNA damage response, partici-
pating in apoptosis, senescence, differentiation and cell
cycle arrest. We have recently reported over expression of
p21cip1/waf1 in our HC model [10]. In the present work, we
corroborated p21cip1/waf1 induction (36%, P  < 0.05) in
animals receiving DAB continuously while carcinogen
deprivation completely restituted p21cip1/waf1 to basal lev-
els (Fig. 2).
We evaluated the expression of the anti-apoptotic protein
Bcl-2 in order to assess the involvement of the cell death
machinery in the HR process. Bcl-2 expression slightly
induced by DAB treatment (33%, P < 0.05) was com-
pletely reversed to control levels after DAB deprivation
(Fig. 2); this finding correlates with the absence of apop-
totic morphological features in immunohistochemical
HR images.
Concluding, the deregulation in cell cycle progression
seen in the tumor process as previously reported in our in
vivo model of HC [10] was validated in the present work.
Furthermore, we showed the abnormal expression of cyc-
lin E and CDK2 in HR group which could be associated to
the inflammatory process [16].
HO-1 expression levels are restored after carcinogen 
withdrawal
HO-1 is a stress inducible protein, useful to maintain cel-
lular homeostasis [17,18]. We have previously reported
increased HO-1 expression in DAB fed animals [10] as
consequence of the oxidative stress provoked by the car-
cinogen [19]. Furthermore, we have studied this protein
expression and cellular localization during the different
stages of HC [14]. In the present work, we analyzed HO-1
expression in HR. Dietary carcinogen deprivation restored
HO-1 expression levels to control values (Fig. 3) probably
due to a decrease in the oxidative stress as result of carcin-
ogen deprivation.
HO-1 as an indicative marker of hepatic homeostatic 
response
Considering that increase HO-1 expression in chemical
HC plays an effective role to counteract oxidative damage
and to control inflammation and confers marked resist-
ance to apoptosis [10], we studied HO-1 expression by
immnunohistochemical analysis in the liver of animals
under a protocol of carcinogen withdrawal. The HC group
showed: necrotic tissue foci with mild (-/+) or absence (-)
of HO-1 immunoreaction surrounded by regenerative
and normal HO-1 positive (++/+++) hepatocytes (Fig. 4a
upper-left angle) and hepatic macrophages hyperplasia
with increased HO-1 immunoreaction (+++) (Fig. 4b) ;
morphological and immunohistochemical "altered
hepatic foci lesions" (AHF) with central disposed large
irregular hepatocytes with decreased (-/+) HO-1 expres-
sion and intense (+++) immunostaining periphery
hepatic macrophages (Fig. 4d). The HR group showed:BMC Cancer 2006, 6:286 http://www.biomedcentral.com/1471-2407/6/286
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Expression of cyclin E, CDK2, CDK4, p21cip1/waf1 and Bcl-2 in HR and during HC Figure 2
Expression of cyclin E, CDK2, CDK4, p21cip1/waf1 and Bcl-2 in HR and during HC. Proteins were extracted from liver of control, 
HC and HR animals (six independent replicates). Equal quantities of proteins were loaded per lane. The proteins cyclin E, 
CDK2, CDK4, p21cip1/waf1 and Bcl-2 were detected using polyclonal antibodies and visualized using ECL reagents. Intensity of 
bands was analyzed with Image Master. Protein expression levels were expressed as a percentage of control values, obtained 
from Western Blot analysis. *P < 0.05 vs. control group and °P < 0.05 vs. HC group.BMC Cancer 2006, 6:286 http://www.biomedcentral.com/1471-2407/6/286
Page 6 of 9
(page number not for citation purposes)
regeneration tissue foci with few intense (+++) immunos-
taining hypertrophic rounded cells (Fig. 4e) and the
remaining hepatocytes with HO-1 expression similar (+/
++) to the normal control group (Fig. 4c), and absence of
tissue necrosis features with normal (+/++) HO-1 expres-
sion (Fig. 4f).
It is evident that HO-1 inmmunoreactivity showed a vari-
able pattern in the regenerative tissue with altered expres-
sion associated with cell morphological and size changes.
We propose that this protein over expression in the nor-
mal liver could be indicative of HO-1 protective function
against the inflammatory injury provoked by the carcino-
gen.
Discussion
Disruption of the regulatory system controlling G1 phase
progression is a common event in human hepatocarcino-
genesis [9]. Oxidative injury may produce cell death and a
compensatory increased in cell proliferation. We have pre-
viously demonstrated that DAB treatment leads to dereg-
ulation of the cell cycle progression [10].
Members of the Bcl-2 family of proteins are important reg-
ulators of the programmed cell death pathway [20] with
individual members that can suppress (eg Bcl-2, Bcl-XL)
or promote (eg Bax, Bad) apoptosis. While the mecha-
nism(s) of Bcl-2's anti-apoptotic function is not yet clear,
introduction of Bcl-2 into most eukaryotic cell types pro-
Expression of HO-1 Figure 3
Expression of HO-1. Proteins were extracted from liver of controls, HC and HR animals (six independent replicates). Equal 
quantities of proteins were loaded per lane. HO-1 protein was detected using a polyclonal antibody and visualized using ECL 
reagents. Intensity of bands was quantified with Image Master. Protein expression levels were expressed as a percentage of 
control values. *P < 0.05 vs. control group and °P < 0.05 vs. HC group.BMC Cancer 2006, 6:286 http://www.biomedcentral.com/1471-2407/6/286
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Representative findings of heme oxygenase (HO-1) immunoreactivity Figure 4
Representative findings of heme oxygenase (HO-1) immunoreactivity. Immunohistochemical results: HC group: a) non-apop-
totic necrotic tissue foci (white broad arrow), regenerative and normal HO-1 positive hepatocytes (upper-left angle, black 
arrows) and b) hepatic macrophages hyperplasia (black arrows heads) and altered hepatocytes (black arrows); d) "altered 
hepatic foci lesions (AHF)" with decreased HO-1 expression central hepatocytes (black arrows) and surrounded by macro-
phages (black arrows heads). HR group: e) regenerative tissue foci with few intense staining rounded cells (white broad 
arrows), hepatocytes (black arrows) and few macrophages (black arrows heads) with similar normal tissue HO-1 expression; f) 
normal HO-1 expression and absence of tissue necrosis features in HR tissue hepatocytes (black arrows) and macrophages 
(black arrows heads). Control group: c) normal HO-1 hepatic tissue (black arrows) and macrophages (black arrows heads) 
expression. (Final Magnification × 312.5).BMC Cancer 2006, 6:286 http://www.biomedcentral.com/1471-2407/6/286
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tect the recipient cell from a wide variety of stress applica-
tions that lead to cell death [21]. Although, over
expression of the anti-apoptotic protein Bcl-2 in HC pre-
viously reported [10] was confirmed, basal levels of this
protein were detected in HR, suggesting that apoptosis
could be triggered under regenerative conditions to
restore homeostasis.
We have demonstrated previously that DAB treatment
leads to deregulation of the cell cycle with remarkable
over expression of cyclin E [10]. Cyclin E over expression
is a common feature in cancer [22], suggesting that cyclin
E/CDK2 deregulation contributes to tumorigenesis. How-
ever, uncontrolled cell proliferation and abnormal expres-
sion of cell cycle related proteins are observed in
inflammatory processes [16] suggesting that cell prolifer-
ation is required in the regenerative process. We reported
here a striking increase in CDK2 and cyclin E expression
in HR animals.
HO-1 is an inducible and ubiquitous 32 kDa isoform
highly expressed in spleen and liver and normally found
in very low levels in mammalian tissues [23]. The regula-
tion of its potent enzymatic activity depends primarily on
the control of HO-1 expression at transcriptional level
[23,25]. HO-1 induction is considered to be an adaptative
cellular response to oxidative stress [26,19]. Up-regula-
tion of HO-1 expression in DAB fed animals, as an endog-
enous antioxidant defense mechanism, would serve as a
protective factor controlling the changes associated to the
carcinogenic process [19,14]. We demonstrated that HO-
1 levels were diminished in HR group in comparison with
animals that received a continuous carcinogenic diet,
indicating that deprivation of the carcinogen will promote
hepatic regeneration and enable to restore the hepatic
homeostasis. Increase HO-1 expression in chemical HC
plays an effective role to counteract oxidative damage and
to control inflammation and confers marked resistance to
apoptosis [10]. HO-1 induction or HO-1 gene transfer
reduces apoptosis with an increase in Bcl-2 in rat ischemic
hearts [27] and liver grafts [28]. In agreement with these
data, we observed in HC the same profile of correlation
between Bcl-2 and HO-1. The mechanism by which HO-
1 induces over expression of Bcl-2 is yet unclear. The
present paper shows a decrease in both HO-1 and Bcl-2
expression in HR model, restoring the apoptotic machin-
ery functionality.
One important component observed by immunohisto-
chemical studies in the liver tissue slides of HR animals,
was the presence of sinusoidal lining fixed macrophages
(Kuppfer's cells) as well as free macrophages surrounding
foci of necrosis and nodular lesions, as indicative of an
inflammatory response. Also, regeneration cells displayed
changes in type, size and intensity of HO-1 immunostain-
ing. Over expression of this protein, stimulates the prolif-
eration and cell differentiation and promotes
angiogenesis [29,30], related to an inflammatory reaction
[31,32].
Finally, for limited resections (less than 60–70%) or mod-
erate hepatocytes damage, the rate of regeneration is suffi-
cient enough to restore the greater part of the liver mass
and function. In this context, we might consider HO-1
over expression as an alternative therapy to diminish the
tissue inflammation and also its deterioration in many ill-
nesses.
HO-1 has also been identified as a key enzyme for the
cytoprotection of many cell types. Increased expression of
HO-1 has been shown to be protective in ischemia/reper-
fusion injury, in organ transplantation, in protection
against renal and pulmonary injury, and in amelioration
of adverse hemodynamic effects resulting from liver dis-
ease and portal hypertension [33-35]. Even more, it was
recently reported that hepatitis C (HCV) infection
increased HO-1 mRNA expression and protein levels in
human liver cells and was suggested to likely represent a
protective response against possible oxidative or other
insult from HCV proteins [36]. Thus, Ghaziani et al [36]
suggested that HO-1 importance extends beyond its func-
tion in the catabolism of heme.
Conclusion
Taken together, these results show that the regenerative
capacity of the liver is still observed in the pre-neoplastic
tissue after carcinogen withdrawal suggesting that reversi-
ble mechanism/s arise to compensate necrosis and resti-
tute homeostasis. Furthermore, these results provide a
rationale for using HO-1 over expression as an alternative
therapy to diminish tissue inflammation and tissue dete-
rioration in many illnesses.
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